title: [Antinuclear antibodies without connective tissue disease : Antibodies against LEDGF/DSF70].
abstract: Testing for antinuclear antibodies (ANA) by the indirect immunofluorescence test (IFT) is regarded as a fundamental serological screening method for diagnosing connective tissue diseases (CTD). In the case of a negative result exclusion of certain CTDs is indicated, especially systemic lupus erythematosus, and a positive ANA result is the starting point for further tests aimed at finding disease-specific autoantibodies. The recently discovered antibodies against lens epithelium-derived growth factor (LEDGF/DSF70) deviate from the normal interpretation pattern in ANA diagnostics. These antibodies give rise to a characteristic dense fine speckled (DSF) immunofluorescence pattern in IFT and target the ubiquitously expressed nuclear stress protector protein LEDGFp75. They can be detected, sometimes in high titers, not only in patients with diverse disorders of the skin or eyes and with neoplasms but also in persons with relatively mild or unspecific complaints and even in apparently healthy individuals; however, they are less frequent in CTD. These anti-LEDGF antibodies can be found in all age groups with a tendency to a higher prevalence in younger people and the frequency does not increase in advanced age. The vast majority of anti-LEDGF carriers are female. The CTDs with isolated anti-LEDGF antibodies, i. e. unaccompanied by autoantibodies typical for the respective CTD, are extremely rare. Detection of ANA exclusively with a DSF immunofluorescence pattern and confirmed by a specific anti-LEDGF binding assay, does not therefore indicate the presence of CTD but is indicative of exclusion of systemic lupus erythematosus, systemic sclerosis and an ANA-associated overlap syndrome, similar to a completely negative ANA result.
authors.affiliation: , Danziger Straße 14, 52249, Eschweiler, Deutschland. mierau.rmn@t-online.de.
authors.forename: R
authors.initials: R
authors.lastname: Mierau
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000097:blood / Q000276:immunology*; D000974:Antibodies, Antinuclear / Q000097:blood* / Q000276:immunology*; D019317:Evidence-Based Medicine; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D015203:Reproducibility of Results; D012216:Rheumatic Diseases / Q000097:blood / Q000000981:diagnostic imaging* / Q000276:immunology*; D012680:Sensitivity and Specificity; D014157:Transcription Factors / Q000097:blood / Q000276:immunology*
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000974:Antibodies, Antinuclear; C504649:PSIP1 protein, human; D014157:Transcription Factors
keywords: Autoantibodies; Fluorescent antinuclear antibody test; Overlap syndrome; Systemic lupus erythematosus; Systemic sclerosis
references.citation: Arthritis Rheum. 1997 Sep;40(9):1725
references.pmid: 9324032
references.citation: J Rheumatol. 2012 Nov;39(11):2104-10
references.pmid: 22942262
references.citation: J Urol. 1994 Mar;151(3):587-92
references.pmid: 8308964
references.citation: J Autoimmun. 2006 Feb;26(1):42-51
references.pmid: 16246523
references.citation: Ann Rheum Dis. 2014 Jan;73(1):17-23
references.pmid: 24126457
references.citation: Arthritis Rheum. 2011 Dec;63(12):4036-7; author reply 4037-8
references.pmid: 22127717
references.citation: Front Immunol. 2015 Mar 20;6:116
references.pmid: 25852687
references.citation: Rev Bras Reumatol. 2010 Nov-Dec;50(6):655-60
references.pmid: 21243306
references.citation: J Autoimmun. 2004 Nov;23(3):257-66
references.pmid: 15501396
references.citation: Autoimmunity. 1997;25(4):243-50
references.pmid: 9344332
references.citation: Clin Exp Med. 2016 Aug;16(3):273-93
references.pmid: 26088181
references.citation: J Rheumatol. 2013 Jan;40(1):92-3
references.pmid: 23280167
references.citation: Prostate. 2005 Jan 1;62(1):14-26
references.pmid: 15389814
references.citation: Korean J Lab Med. 2009 Apr;29(2):145-51
references.pmid: 19411782
references.citation: Ann N Y Acad Sci. 2007 Jun;1107:174-83
references.pmid: 17804545
references.citation: Immunol Lett. 2001 Oct 1;78(3):161-8
references.pmid: 11578690
references.citation: Dtsch Med Wochenschr. 2009 Jun;134(24):1278-82
references.pmid: 19499499
references.citation: Arthritis Rheum. 2011 Jan;63(1):191-200
references.pmid: 20954189
references.citation: Autoimmunity. 2009 Sep;42(6):492-6
references.pmid: 19657776
references.citation: J Rheumatol. 2005 Nov;32(11):2144-9
references.pmid: 16265692
references.citation: PLoS One. 2015 Sep 23;10(9):e0138671
references.pmid: 26397729
references.citation: J Immunol Res. 2014;2014:827827
references.pmid: 24860838
references.citation: Arthritis Rheum. 2012 Aug;64(8):2677-86
references.pmid: 22553077
references.citation: J Immunol Res. 2014;2014:315179
references.pmid: 24868563
references.citation: J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1211-20
references.pmid: 10856157
references.citation: Clin Dev Immunol. 2013;2013:703759
references.pmid: 23476678
references.citation: Ann Rheum Dis. 2010 Aug;69(8):1420-2
references.pmid: 20511607
references.citation: PLoS One. 2014 Apr 04;9(4):e93812
references.pmid: 24705829
references.citation: Pediatrics. 2014 Dec;134(6):e1706-8
references.pmid: 25384487
references.citation: Autoimmunity. 2011 Sep;44(6):511-9
references.pmid: 21329475
references.citation: Autoimmunity. 2002 Aug;35(5):319-27
references.pmid: 12515286
references.citation: Lupus. 2008 Mar;17(3):171-6
references.pmid: 18372356
references.citation: Arthritis Rheum. 2004 Mar;50(3):892-900
references.pmid: 15022332
references.citation: J Autoimmun. 2006 Aug;27(1):17-27
references.pmid: 16757148